Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Inclusion Criteria: * Aged ≥ 42 to ≤ 89 days on the day of the first study visit. * Healthy infants as determined by medical history, physical examination, and judgment of the investigator * Informed consent form has been signed and dated by the parent(s) or guardian, and an independent witness, if required by local regulations * Participant and parent/guardian were able to attend all scheduled visits and to comply with all trial procedures. * Infants who received the first dose of hepatitis B vaccine at least 28 days before the first study visit Exclusion Criteria: * Participation at the time of study enrollment or in the 4 weeks preceding the first trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure * Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned receipt of any vaccine in the 4 weeks before and/or following any trial vaccination except for influenza vaccination, which could have been received at a gap of at least 2 weeks before or 2 weeks after any study vaccination. This exception included monovalent pandemic influenza vaccines and multivalent influenza vaccines * Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, PS, or conjugate meningococcal vaccine containing serogroups A, C, Y, or W; or meningococcal B serogroup-containing vaccine). *…